The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
Aneal KhanSandra M SirrsDaniel G BichetChantal F MorelAdina TocoianLan LanMichael L Westnull nullPublished in: Drugs in R&D (2021)
ClinicalTrials.gov identifier NCT01298141.